Zai Lab Announces Public Offering of ADSs to Support Research Initiatives

Zai Lab, a biopharmaceutical company listed on NASDAQ and HKEX, has announced a public offering of American Depositary Shares (ADSs). The offering is part of their strategy to raise capital for their ongoing research and development efforts. The company has filed a registration statement on Form S-3ASR with the U.S. Securities and Exchange Commission (SEC), which includes a prospectus supplement detailing the offering. Interested parties can access these documents on the SEC's website or request copies from Goldman Sachs & Co. LLC, Jefferies LLC, or Leerink Partners LLC.

Zai Lab is focused on developing innovative treatments in oncology, immunology, neuroscience, and infectious disease. The company aims to address significant unmet medical needs both in China and globally. The proceeds from the offering are expected to support these initiatives.

However, Zai Lab cautions that forward-looking statements in the press release are subject to risks and uncertainties. These include the potential impact on the market price of their ADSs and ordinary shares due to the dilutive effect of the new securities, as well as broader economic and industry conditions. The company acknowledges that actual results may differ from their projections and does not guarantee the completion of the offering on anticipated terms.